Pacific Biosciences
PACB
128 hedge funds and large institutions have $580M invested in Pacific Biosciences in 2016 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 42 reducing their positions, and 31 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
34% more capital invested
Capital invested by funds: $432M → $580M (+$148M)
14% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 42
9% less funds holding
Funds holding: 141 → 128 (-13)
21% less call options, than puts
Call options by funds: $5.52M | Put options by funds: $7M
39% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 31
Top Buyers
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$15.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$11.9M |
| 3 |
MC
Maverick Capital
Dallas,
Texas
|
+$10.7M |
| 4 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
+$8.97M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$6.27M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$23.6M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$7.84M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$7.46M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$2.92M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$2.65M |
PACB Hedge Fund Activity: Q3 2016 in Review
128 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q3 2016, worth a combined $580M — up 34% from $432M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of PACB and 19 opened new positions — a net loss of 12 holders — while 42 trimmed existing stakes and 48 added.
The largest buyer was Oracle Investment Management, adding an estimated $15.2M. The largest seller was Millennium Management, cutting an estimated $23.6M.
- 128 institutional investors held Pacific Biosciences (PACB) as of Q3 2016, down from 141 in Q2 2016.
- Funds reported $580M of Pacific Biosciences stock for Q3 2016, up 34% quarter-over-quarter.
- 19 funds opened new Pacific Biosciences positions in Q3 2016 and 31 closed out, a net change of -12 holders.
- The largest Pacific Biosciences buyer in Q3 2016 was Oracle Investment Management, an estimated $15.2M added.
- The largest Pacific Biosciences seller in Q3 2016 was Millennium Management, an estimated $23.6M sold.
Based on aggregated 13F filings for Q3 2016.